Clinical trials: Adjuvant Treatment
Endometrial Adenocarcinoma
PErsonalized TReatment for Endometrial Carcinoma
The goal of this clinical trial is to compare the efficacy of adjuvant therapies in women with stage I-II molecular integrated high-intermediate or high-risk endometrial carcinoma.
- Trial name
- PETREC (NCT05655260)
- Testing
- Comparison of chemotherapy vs. chemoradiotherapy, Comparison of VBT vs. WPRT
- Where
- Finland
- Volunteers
- 300 people
- Sponsor
- University of Helsinki
Breast Cancer, Metastatic Cancer
Chemotherapy and/or Hormone Therapy With or Without Zoledronate in Treating Women With Stage II or Stage III Breast Cancer
RATIONALE: Zoledronate may delay or prevent the formation of bone metastases. It is not yet known whether chemotherapy and/or hormone therapy are more effective with or without zoledronate in preventing cancer recurrence and bone…
- Trial name
- NCT00072020
- Testing
- zoledronic acid, adjuvant therapy, neoadjuvant therapy
- Sponsor
- University of Sheffield
Thymic Carcinoma
Postoperative Adjuvant Chemotherapy for Thymic Cancer (FUSCC-Thymic 3)
The goal of this clinical trial is to learn the role of adjuvant chemotherapy for patients with thymic carcinoma and completed resection. The main questions it aims to answer are: 1.
- Trial name
- NCT06402708
- Testing
- Chemotherapy, Radiotherapy
- Where
- China
- Volunteers
- 172 people
- Sponsor
- Fudan University
Breast Cancer
Combination Chemotherapy in Treating Women With Stage I Breast Cancer
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells.
- Trial name
- NCT00055679
- Testing
- cyclophosphamide, epirubicin hydrochloride, fluorouracil
- Where
- 72 sites in France
- Volunteers
- 1,512 people
- Sponsor
- UNICANCER
Non-Small Cell Lung Cancer
Minimal Residual Disease Guiding Adjuvant Therapy in Stage I NSCLC
This investigator-initiated study aims to evaluate the effectiveness of minimal residual disease (MRD) as a biomarker for guiding adjuvant therapy decisions in patients with Stage I non-small-cell lung cancer (NSCLC).
- Trial name
- MOTION-NSCLC (NCT06709274)
- Testing
- Osimertinib, Alectinib, TORIPALIMAB INJECTION (JS001 ) combine with chemotherapy
- Where
- 15 sites in China
- Volunteers
- 342 people
- Sponsor
- Guangdong Association of Clinical Trials
Ovarian Neoplasm Epithelial, Ovarian Cancer
Oregovomab Plus Chemotherapy in Neo-adjuvant Setting in Newly Diagnosed Patients With Advanced Epithelial Ovarian Cancer
A clinical study to compare the efficacy and safety of five administrations of oregovomab versus placebo, infused in schedule dependent sequence with specific cycles of a standard six-cycle chemotherapy regimen (paclitaxel and…
- Conditions
- Ovarian Neoplasm Epithelial, Ovarian Cancer, Fallopian Tube Neoplasms, Peritoneal Carcinoma
- Trial name
- NCT05605535
- Testing
- Oregovomab, Paclitaxel, Carboplatin
- Where
- 14 sites in India
- Volunteers
- 88 people
- Sponsor
- CanariaBio Inc.
Lung Cancer
Clinical Study on the Prevention of Driver Gene Negative Ib-IIIb Lung Cancer Recurrence and Metastasis by Staged Chinese Herbal Medicine Combined With Chemotherapy and Immune Checkpoint Inhibitors
This project adopts a prospective, multicenter, randomized controlled clinical study to investigate the treatment of TCM in postoperative patients with driver gene negative lung cancer, according to two phases of postoperative…
- Trial name
- NCT05834413
- Testing
- chemotherapy plus TCM 1&ICIs plusTCM2
- Where
- China
- Volunteers
- 367 people
- Sponsor
- Shanghai University of Traditional Chinese Medicine
Resectable HER2-positive Breast Cancer
A Phase III Study of KN026 in Combination With HB1801 as Adjuvant Therapy for Resectable HER2-Positive Breast Cancer
This is a randomized, controlled, open-label, multicenter, Phase Ⅲ clinical study designed to compare the efficacy and safety of KN026 combined with HB1801 and chemotherapy versus trastuzumab combined with pertuzumab and…
- Trial name
- NCT07441460
- Testing
- KN026, HB1801, Trastuzumab
- Where
- China
- Volunteers
- 1,800 people
- Sponsor
- Shanghai JMT-Bio Inc.
Bladder Cancer, Bladder Cancer Recurrence
Multiplex Mutation Detection Using Mass Spectrometry in Bladder Cancer
Bladder cancer is a highly heterogeneous malignancy characterized by frequent genetic alterations that are closely associated with disease progression, recurrence risk, and treatment response.
- Conditions
- Bladder Cancer, Bladder Cancer Recurrence, Adjuvant Therapy for Bladder Cancer, Progression of Bladder Cancer
- Trial name
- NCT07424560
- Testing
- Multiplex Mutation Detection System for Bladder Cancer (Nucleic Acid Mass Spectrometry)
- Where
- China
- Volunteers
- 400 people
- Sponsor
- Zhilong Dong
Bone Loss, Breast Cancer
Zoledronic Acid in the Prevention of Cancer Treatment Related Bone Loss in Postmenopausal Women Receiving Letrozole for Breast Cancer.
Post-menopausal breast cancer patients will receive letrozole 2.5 mg daily for the treatment of breast cancer and will be randomized to a treatment group to receive either upfront zoledronic acid 4 mg IV 15-minute infusion every…
- Trial name
- NCT00171340
- Testing
- Zoledronic acid, Letrozole
- Where
- 106 sites in Argentina, Australia and 26 more
- Volunteers
- 1,065 people
- Sponsor
- Novartis Pharmaceuticals
Breast Cancer
Therapeutic Cancer Vaccine (AST-301, pNGVL3-hICD) in Patients With Breast Cancer
The purpose of this study is to evaluate the efficacy and safety of an adjuvant treatment of therapeutic cancer vaccine (AST-301, pNGVL3-hICD) in patients with HER2-low expression (IHC 1+ or 2+ and ISH-) and hormone…
- Trial name
- Cornerstone001 (NCT05163223)
- Testing
- AST-301(pNGVL3-hICD), rhuGM-CSF, Pembrolizumab
- Where
- 17 sites in United States, Taiwan
- Volunteers
- 10 people
- Sponsor
- Aston Sci. Inc.
Hepatocellular Carcinoma
Postoperative Adjuvant Therapy With Recombinant Interferon-Alpha Following Curative Resection of HCC
We conducted a randomized controlled trial of adjuvant interferon therapy in patients with predominantly hepatitis B-related hepatocellular carcinoma (HCC) to investigate whether the prognosis after hepatic resection could be…
- Trial name
- NCT00234182
- Testing
- Interferon alpha-2b
- Volunteers
- 84 people, healthy volunteers welcome
- Sponsor
- The University of Hong Kong
Breast Cancer Females, Triple Negative Breast Cancer (TNBC)
Adjuvant Intensification for LAR
This study enrolled patients with early-stage triple-negative breast cancer who had undergone radical surgery. The postoperative pathology met the TNM staging criteria of pT1c-3N0-3M0, and immunohistochemistry (IHC) results…
- Trial name
- POLARIS (NCT07407517)
- Testing
- Everolimus 10 mg daily
- Volunteers
- 904 people
- Sponsor
- Fudan University
Head Injury
Adjuvant Acupuncture for Severe Head Injury
The purpose of this study is to determine the therapeutic effect of acupuncture on severe head injury under conventional treatment.
- Trial name
- NCT01773291
- Testing
- acupuncture, laser acupuncture, control
- Where
- Taiwan
- Volunteers
- 24 people
- Sponsor
- Chang Gung Memorial Hospital
Breast Cancer, Adjuvant Drug Therapy
The POWER Trial: Personalised Dose Optimisation With Adjuvant Tamoxifen Therapy in Breast cancER
In Sweden, approximately 7000 women are diagnosed with hormone-sensitive breast cancer annually. According to international and national guidelines, most of these women are recommended anti-hormonal therapy for five to ten years…
- Trial name
- POWER (NCT07502820)
- Testing
- Individual dose of tamoxifen, Standard adjuvant therapy of tamoxifen
- Where
- 4 sites in Sweden
- Volunteers
- 1,100 people
- Sponsor
- Karolinska Institutet
NSCLC, ALK
The Efficacy and Safety of Ensartinib As Adjuvant Therapy in Stage I ALK-positive NSCLC Patients with High Risk Factors
This study is designed to evaluate the efficacy and safety of a 2-year adjuvant treatment with Ensartinib in stage I ALK-positive non-small cell lung cancer (NSCLC) patients with high-risk factors.
- Conditions
- NSCLC, ALK, Stage I, Adjuvant Treatment
- Trial name
- NCT06772610
- Testing
- Ensartinib group
- Volunteers
- 40 people
- Sponsor
- Shanghai Pulmonary Hospital, Shanghai, China
Recurrent Vulvovaginal Candidiasis
Study of Lactobacillus in Adjuvant Treatment of RVVC
We are trying to determine if Clotrimazole vaginal tablets with oral Lactobacillus is better than Clotrimazole vaginal tablets in Preventing the Recurrence of vulvovaginalcandidiasis
- Trial name
- NCT04699240
- Testing
- clotrimazole vaginal tablets, Clotrimazole vaginal tablets+ Lactobacillus
- Where
- China
- Volunteers
- 140 people
- Sponsor
- Peking University Shenzhen Hospital
Glioblastoma, Gliosarcoma
Temozolomide With or Without Veliparib in Treating Patients With Newly Diagnosed Glioblastoma Multiforme
This randomized phase II/III trial studies how well temozolomide and veliparib work compared to temozolomide alone in treating patients with newly diagnosed glioblastoma multiforme.
- Trial name
- NCT02152982
- Testing
- Laboratory Biomarker Analysis, Quality-of-Life Assessment, Temozolomide
- Where
- 391 sites in United States, Puerto Rico
- Volunteers
- 447 people
- Sponsor
- National Cancer Institute (NCI)
Metastatic Colorectal Cancer
mFOLXOX6 Versus FOLFIRI for Colorectal Patients Recurrence After Oxaplatin Based Adjuvant Chemotherapy
A multicenter,open,prospective randomized controlled trial;11 study center in China; Plan to enroll 328 patients（ Power Analysis and Sample Size ）.Comparing FOLFIRI with mFOLFOX6,Superiority design.Investigate difference…
- Trial name
- NCT05362617
- Testing
- FOLFIRI
- Where
- China
- Volunteers
- 328 people
- Sponsor
- Second Affiliated Hospital, Zhejiang University, School of Medicine
3-year Disease-free Survival
Befotertinib Adjuvant Therapy in Stage IA2-IB NSCLC Patients
To evaluate 3-year disease-free survival after complete resection in patients with MRD-positive EGFR-sensitive mutations in Stage IA2-IB NSCLC treated with adjuvant befortinib and under routine observation (3y-DFS).
- Trial name
- NCT06561620
- Testing
- Befotertinib
- Where
- China
- Volunteers
- 592 people
- Sponsor
- Fudan University
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.